Tag : NON-SMALL CELL LUNG CANCER

CONFERENCE UPDATE

Resectable NSCLC in transition: Integrating immunotherapy and targeted approaches
The landscape of early-stage non-small cell lung cancer is undergoing a rapid transformation. Once defined by the modest survival gains of adjuvant chemotherapy, treatment strategies now extend to immunotherapy and targeted therapies in both adjuvant and neoadjuvant settings.
INDUSTRY ESSENTIALS

Bridging practice and precision for early-stage resectable NSCLC: Malaysia’s first surgical consensus
In an interview with Prof. Dr. Anand Sachithanandan discussed the key gaps in lung cancer management and the nationwide efforts to advance early detection, timely treatment, and equitable surgical care.

Professor Dr. Anand Sachithanandan

Founding President of Lung Cancer Network Malaysia, Consultant Cardiothoracic Surgeon, Sunway Medical Centre, Selangor, Malaysia
CONFERENCE UPDATE

First-line lorlatinib continues to show PFS benefit over crizotinib in patients with advanced ALK+ NSCLC: 5-year follow-up of the CROWN study
Lorlatinib is a brain-penetrant third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) which covers a broader ALK resistance profile than second-generation ALK TKIs. It has previously demonstrated improved PFS and IC activity compared to crizotinib in treatment-naïve patients with advanced ALK+ NSCLC in the ongoing randomized phase 3 CROWN study.
INFOGRAPHICS

PACIFIC-6: Durvalumab after CRT showed similar safety profile as the PACIFIC regimen with encouraging efficacy data in frailer and older patients with stage 3, unresectable NSCLC